3 Growth Stocks That Could Generate 10X Returns

The article highlights three speculative long-term winners: CRISPR Therapeutics, Green Thumb Industries, and Joby Aviation. CRISPR has Casgevy approved and generated $116 million in 2025 revenue, Green Thumb posted $114 million in net income on just under $1.2 billion of revenue, and Joby is awaiting potential approval for its air taxi. The tone is constructive overall, though it emphasizes significant execution and regulatory risks, especially for Joby.

Analysis

The real distinction here is between optionality that is already partially funded and optionality that still needs external validation. CRSP has the cleanest setup: if Casgevy ramps from niche launch to a reimbursed, multi-center standard of care, the market should stop valuing it like a binary science project and start valuing cash conversion on a 2-3 year horizon; that rerating can happen before peak revenue is visible. The commercial risk is not scientific novelty but operational friction — patient identification, treatment-center throughput, and payer discipline can all delay revenue recognition even if demand exists.

JOBY is the opposite: the equity is priced for narrative momentum, not for a normalized industrial model. Near-term approval would likely trigger a sharp multiple expansion, but that is a tradable event rather than proof of durable unit economics; the stock can gap on headlines while the business still burns cash into a larger manufacturing and certification burden. The second-order winner, if air mobility actually scales, may be suppliers and infrastructure partners rather than the OEM itself, because certification and fleet utilization tend to compress margins at the platform layer.

GTBIF is the underappreciated asymmetry because profitability in a structurally constrained industry creates survivability and financing optionality. Any real regulatory easing should widen the gap between operators with existing balance sheets and those still dependent on external capital; that makes this more of a share-consolidation story than a pure industry growth story. The contrarian risk is that investors are extrapolating reform timing too aggressively: partial rescheduling helps sentiment, but without banking access, interstate normalization, or federal tax relief, the earnings uplift may remain incremental rather than explosive.

Consensus appears to be underpricing time dispersion. CRSP may compound quietly for years, JOBY may spike on approvals and then mean-revert if commercialization slips, and GTBIF could outperform on lower-volatility fundamentals if regulatory progress remains slow but steady. The best risk/reward is to own the cash-rich, clinically de-risked platform and trade the event-driven names with tight horizons, not to confuse headline catalysts with durable franchise value.

Key Decisions for Investors

• Long CRSP on 6-12 month horizon; favor staged entry on weakness because the setup is a commercialization rerate, not a binary approval trade. Upside is meaningful if revenue visibility improves; risk is slower-than-expected rollout and payer friction.
• Trade JOBY as a catalyst event, not a core long: buy short-dated upside optionality only into concrete FAA/approval milestones, and pair with a hard stop if execution slips. High upside if approved, but valuation can compress quickly if commercialization timelines extend.
• Long GTBIF as a relative-value position versus weaker cannabis operators; the clean balance sheet and profitability profile should win share if regulatory reform stays partial. Best expressed as a basket long against higher-burn peers rather than an outright sector bet.
• Pair trade: long CRSP / short JOBY for a quality-vs-narrative divergence view over the next 6-12 months. CRSP has a clearer path to sustainable fundamentals, while JOBY remains dependent on multiple external approvals and capital intensity.
• Use call spreads instead of common stock for JOBY around approval events to cap downside and avoid paying for post-news volatility decay. If the stock gaps on approval, trim into strength rather than hold for a full-scale commercialization rerating.